LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Michel Orsinger Joins Lima Corporate Advisory Board
People In The News

Michel Orsinger Joins Lima Corporate Advisory Board

March 13, 2017 2 min read Premium comments

Advertisement

Michel Orsinger Joins Lima Corporate Advisory Board
Michel Orsinger

Michel Orsinger, former chairman of Global Orthopedics Johnson & Johnson, has joined the Advisory Board of Lima Corporate, a company based in Udine, Italy.

According to the March 1, 2017 news release, “Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at Johnson & Johnson (J&J) from 2012 to 2015. He was also a member of J&J’s Global Management Team. Michel Orsinger joined Johnson & Johnson following the sale of Synthes Inc. for $20 billion, the largest acquisition ever realized by Johnson & Johnson to date. Subsequently, Michel Orsinger established the worldwide largest and most comprehensive orthopedic company. Prior to his leadership role at J&J, Mr. Orsinger was COO and CEO of Synthes Inc for eight years, and spent eleven years with Novartis. Today, Michel Orsinger is an investor as well as board member of several start-up companies and an advisor to EQT. Moreover, he joined the Board of Takeda in 2016, the largest Japanese and Asian pharmaceutical company. Michel Orsinger is also active in philanthropic initiatives, including volunteer work in Africa, supporting surgeons and local health care professionals in establishing adequate education programs to improve patient care. He holds a Business Administration Degree from the University of St. Gallen (Switzerland) and has attended Management Programs at the Harvard Business School and at INSEAD.”

“I am very happy that Michel as another high quality veteran of our industry has decided to join the Advisory Board” said Luigi Ferrari, CEO of Lima Corporate. “Michel’s expertise in the orthopaedic as well as medical device industry and track record of growing companies will accelerate our development.”

Orsinger told OTW, “My healthcare and medical technology industry experience gained over the many past years, combined with my global leadership experience in reputable companies, will be of added value to Lima. Also my previous and current Board positions in start-ups and in a larger health care company are of relevance.”

“First of all I want to meet the team and learn as much as I can about the business, including their challenges and opportunities. Subsequently, I will want to make contributions in best supporting management, especially related to patient and customer focus, innovation and business development, geographical expansion and talent! I am very excited to have the opportunity to work with a group of very committed multicultural people, to support the dynamic and impressive growth of Lima, and last but not least to continue to contribute to patient care.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy